MaxCyte, Inc. (NASDAQ:MXCT) General Counsel Sells $20,275.64 in Stock

MaxCyte, Inc. (NASDAQ:MXCT - Get Free Report) General Counsel David I. Sandoval sold 4,466 shares of the company's stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $4.54, for a total transaction of $20,275.64. Following the completion of the sale, the general counsel now directly owns 41,447 shares in the company, valued at $188,169.38. This represents a 9.73 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

MaxCyte Stock Down 5.5 %

Shares of MXCT stock traded down $0.27 during trading hours on Tuesday, hitting $4.64. 1,018,515 shares of the company's stock traded hands, compared to its average volume of 678,327. The stock has a market cap of $490.50 million, a price-to-earnings ratio of -13.65 and a beta of 1.29. The stock's fifty day simple moving average is $3.94 and its two-hundred day simple moving average is $4.03. MaxCyte, Inc. has a 12-month low of $3.16 and a 12-month high of $5.32.

MaxCyte (NASDAQ:MXCT - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.02. The firm had revenue of $8.16 million during the quarter, compared to the consensus estimate of $7.50 million. MaxCyte had a negative return on equity of 16.00% and a negative net margin of 78.36%. During the same period last year, the company earned ($0.11) earnings per share. On average, equities analysts forecast that MaxCyte, Inc. will post -0.42 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MaxCyte

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Verition Fund Management LLC lifted its position in MaxCyte by 39.5% in the 3rd quarter. Verition Fund Management LLC now owns 21,335 shares of the company's stock valued at $83,000 after acquiring an additional 6,045 shares in the last quarter. Creative Planning lifted its position in MaxCyte by 33.6% in the 3rd quarter. Creative Planning now owns 28,652 shares of the company's stock valued at $111,000 after acquiring an additional 7,212 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in MaxCyte by 64.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 20,212 shares of the company's stock valued at $79,000 after acquiring an additional 7,930 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in MaxCyte by 25.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 42,289 shares of the company's stock valued at $166,000 after acquiring an additional 8,454 shares in the last quarter. Finally, Chevy Chase Trust Holdings LLC lifted its position in MaxCyte by 0.7% in the 3rd quarter. Chevy Chase Trust Holdings LLC now owns 1,332,048 shares of the company's stock valued at $5,182,000 after acquiring an additional 9,488 shares in the last quarter. 68.81% of the stock is owned by institutional investors.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.